Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Financial ResultsItem 2.02 · 8-KLOW RiskNeutral

Cellectar Biosciences, Inc.

Filed: May 14, 2026CIK: 1279704
Watch CompanyView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Cellectar Biosciences announced Q1 2026 financial results on May 14, 2026, providing shareholders with an update on the company's operational performance and financial condition during the first quarter of the fiscal year.

Key Takeaways

Company disclosed Q1 2026 financial results via press release on May 14, 2026

Filing includes detailed information on operations and financial condition for the quarter ended March 31, 2026

2 more takeaways

Filing Overview

Form Type8-K
Filing DateMay 14, 2026
Item2.02
CategoryFinancial Results
CIK1279704
Accession #0001279704
Risk LevelLOW
SentimentNeutral
Signalinformational
Topics
earnings

What This Means

The company is reporting financial results. Look for revenue trends, profitability changes, and forward guidance.
View Full Filing on SEC.govBrowse More Filings